Clinical Observation on 22 Cases of Advanced Gastric Cancer with Chemotherapy Failure Treated with Combined Qizhu Formula and FOLFOX4

HE Haihui; ZHUO Debin; SHEN Hong; SHAN Zhaowei; LI Yuejun; ZHEN Shijian; WANG Dahai; YIN Huiming

doi:10.13288/j.11-2166/r.2014.23.012

您当前的位置：

首页 >

文章列表页 >

Clinical Observation on 22 Cases of Advanced Gastric Cancer with Chemotherapy Failure Treated with Combined Qizhu Formula and FOLFOX4

更新时间：2021-11-17

- Clinical Observation on 22 Cases of Advanced Gastric Cancer with Chemotherapy Failure Treated with Combined Qizhu Formula and FOLFOX4
- Journal of Traditional Chinese Medicine Vol. 55, Issue 23, Pages: 2020-2024(2014)
- 作者机构：
  
  1. 湖南中医药高等专科学校附属第一医院
  2. 南京中医药大学附属医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2014.23.012
  CLC： R735.2
- Published：2014
- 稿件说明：
移动端阅览
[1]贺海辉,卓德斌,沈洪,单兆伟,李跃军,甄时建,王大海,尹晖明.芪竹方联合FOLFOX4方案治疗化疗失败的晚期胃癌患者22例临床观察[J].中医杂志,2014,55(23):2020-2024.

HE Haihui, ZHUO Debin, SHEN Hong, et al. Clinical Observation on 22 Cases of Advanced Gastric Cancer with Chemotherapy Failure Treated with Combined Qizhu Formula and FOLFOX4[J]. Journal of Traditional Chinese Medicine2014, 55(23): 2020-2024.
[1]贺海辉,卓德斌,沈洪,单兆伟,李跃军,甄时建,王大海,尹晖明.芪竹方联合FOLFOX4方案治疗化疗失败的晚期胃癌患者22例临床观察[J].中医杂志,2014,55(23):2020-2024. DOI： 10.13288/j.11-2166/r.2014.23.012.

HE Haihui, ZHUO Debin, SHEN Hong, et al. Clinical Observation on 22 Cases of Advanced Gastric Cancer with Chemotherapy Failure Treated with Combined Qizhu Formula and FOLFOX4[J]. Journal of Traditional Chinese Medicine2014, 55(23): 2020-2024. DOI： 10.13288/j.11-2166/r.2014.23.012.

摘要

目的观察芪竹方联合FOLFOX4方案治疗一线化疗失败的晚期胃癌患者的有效性及安全性。方法将44例一线化疗失败的晚期胃癌患者随机分为治疗组和对照组各22例。治疗组给予芪竹方口服

每日1剂

同时联合FOLFOX4方案化疗;对照组单纯给予FOLFOX4方案化疗。治疗直至病情进展

或出现不能耐受的毒性

或患者拒绝接受化疗。比较两组患者临床证候改善情况、生存质量、肿瘤反应情况、无进展生存期（PFS）、总生存期（OS）、不良反应以及P-糖蛋白（Pg-p）、谷胱甘肽S-转移酶（GST-π）、拓扑异构酶Ⅱ（Topo-Ⅱ）表达情况。结果治疗组临床证候改善情况、PFS、OS均明显优于对照组（P<0.05或P<0.01）。治疗组治疗后Pg-p、GST-π、Topo-Ⅱ的表达例数均无明显变化（P>0.05）;对照组治疗后Pgp、Topo-Ⅱ无明显变化（P>0.05）

但GST-π表达例数明显高于治疗前（P<0.05）。结论芪竹方联合FOLFOX4治疗一线化疗失败的晚期胃癌有增效减毒作用

稳定GST-π的表达可能为其增效原因之一。

Abstract

Objective To observe the efficacy and safety of combined treatment of Qizhu Formula and FOLFOX4 on advanced gastric cancer patients after failure of first-line chemotherapy. Methods Totally 44 patients with advanced gastric cancer who failed first-line chemotherapy were divided randomly into treatment group and control group

each with 22 patients. Treatment group was given Qizhu Formula orally

1 dose per day

with FOLFOX4 chemotherapy

whereas control group was merely given FOLFOX4 chemotherapy. The treatments were continuously applied unless progression

or untolerable toxicity

or patients ’ rejection of chemotherapy occured. Improvement of clinical symptoms

quality of life

tumor response

progression free survival（ PFS）

overall survival（ OS）

adverse effects and the expression of P-glycoprotein（ Pg-p）

glutathione S-transferase（ GST-π）

topoisomerase Ⅱ（ Topo-Ⅱ） of two groups were compared. Results Improvement of clinical symptoms

PFS

OS in the treatment group was notedly better than that in the control group（ P < 0. 05 or P < 0. 01）. The expression of Pg-p

GST-π

Topo-Ⅱin treatment group showed no obvious change after treatments（ P > 0. 05）. The expression of Pg-p

Topo-Ⅱ in control group also showed no obvious change after treatments（ P > 0. 05）

but the expression of GST-π after treatments was observably higher than before（ P < 0. 05）. Conclusion Combined treatment of Qizhu Formula and FOLFOX4 on advanced gastric cancer patients who failed first-line chemotherapy has the effect of enhancing efficacy and reducing toxicity. Stabilizing the expression of GST-π may be one of the reasons of its efficacy-enhancing effect.

关键词

Keywords

references

查看原文

Views

151

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Syndrome Differentiation and Treatment of Cholinergic Urticaria from the Perspective of "Treating Fire Constraint by Dispersing It"

LI Guolie's Experience in Treating Orthostatic Hypotension from the Perspective of "Raising the Clear and Directing the Turbid Downward"

The Philosophy and Practical Pathway of "Dao （道）-Shen （神）-Formula" in Traditional Chinese Medicine

Challenges and Recommendations for Implementing Key Technologies in Decentralized Clinical Trials of Traditional Chinese Medicine

Current Status and Strategic Recommendations for Randomized Controlled Trials on Functional Dyspepsia-Irritable Bowel Syndrome Comorbidity：from a Real-World Research Perspective

Related Author

No data

Related Institution

No data

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰